Evidence map›Paper›PMID 32983498›Full record

ArticleClinical case reports2020

Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy.

Ayad M Al-Katib, Hussein Gaith, Dahlia Sano, Sayf Al-Katib, Michelle Bonnett, Zyad Kafri

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ayad M Al-KatibLymphoma Research Laboratory Department of Internal Medicine Wayne State University School of Medicine (WSU SOM) Detroit MI USA.
Hussein GaithLymphoma Research Laboratory Department of Internal Medicine Wayne State University School of Medicine (WSU SOM) Detroit MI USA.ORCID https://orcid.org/0000-0001-7808-031X
Dahlia SanoDepartment of Oncology Karmanos Cancer Institute WSU SOM Detroit MI USA.
Sayf Al-KatibDepartment of Diagnostic Radiology and Molecular Imaging Beaumont Health Oakland University William Beaumont School of Medicine Royal Oak MI USA.
Michelle BonnettDepartment of Pathology Ascension St. John Hospital and Medical Center Detroit MI USA.
Zyad KafriVan Elslander Cancer Center Grosse Pointe Woods MI USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ibrutinib is approved for chronic lymphocytic leukemia (CLL). However, its role in the treatment of multiple myeloma (MM) is not clear and is under investigation. We report a case of CLL that developed MM while on therapy with ibrutinib indicating that this drug may not be active against MM.

Indexed as

bruton tyrosine kinase inhibitorschronic lymphocytic leukemiaibrutinibmultiple myeloma

Identifiers

PMID32983498
PMCPMC7495781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.